Novel chain-extended nucleoside phosphoramidates of the anti-human immunodeficiency virus (HIV) drug d4T (stavudine) have been prepared as possible membrane-permeable prodrugs of the bio-active free 5′-monophosphates. Phosphorochloridate chemistry gave the target compounds in moderate to high yields, and all materials were fully characterized by spectroscopic and analytical methods. The compounds are related to the previously reported phenyl methoxyalaninyl derivative of d4T, which was shown to be a potent and selective inhibitor of HIV. In this study the amino acid nitrogen and ester moieties were separated by methylene spacers of between two and six carbon atoms. In vitro evaluation of these compounds indicated an almost complete lack of anti-HIV activity, the compounds being several orders of magnitude less potent than the corresponding α-amino acid derivatives. The reasons for the virtual lack of anti-HIV activity appear to involve poor enzyme-mediated hydrolysis.
Although all known antiviral nucleoside analogues are active in their phosphate (nucleotide) forms, such materials are of limited therapeutic use on account of their poor membrane penetration (Lichtenstein et al., 1960; Liebman & Heidelberger, 1955) . Many quite different chemical approaches have been tried to circumvent the membrane impermeability of the free (charged) nucleotides, including the preparation of masked, lipophilic, membrane-soluble prodrug forms of the free phosphates (Farrow et al., 1990; Kumar et al., 1990; McGuigan et al., 1991; Perigaud et al., 1993) . Despite notable antiviral potencies in some cases, it has often been difficult to establish that such prodrugs do indeed function as phosphate delivery motifs, rather than simply releasing the parent nucleoside analogue. The use of nucleoside kinasedeficient cell lines, which are resistant to the effects of parent nucleosides but sensitive to the intra-cellular release of free nucleotides, has greatly assisted clarification of this. It has thus emerged that some quite different phosphate structures may be effective upon the intracellular release of free nucleotides. These include aryloxy phosphoramidates (McGuigan et al., 1993 Balzarini et al., 1996a) , substituted aryloxy phosphate heterocycles (Meier et al., 1997) and β-substituted dialkyl phosphates such as the bis(SATE) analogues (Valette et al., 1996) .
Regarding the use of aryloxy phosphoramidate derivatives, we have shown by a radiolabelling study that these materials do achieve the intracellular delivery of free nucleotides in a nucleoside kinase-independent manner (Balzarini et al., 1996a,b) . Efforts to optimize the amine portion of the phosphoramidates have revealed that alanine is the preferred amino acid (McGuigan et al., 1997) and that the L-stereochemistry of the amino acid is more effective than its D-epimer . However, the precise role of the amino acid moiety in the antiviral action of these systems remains unclear. It was therefore of interest to probe the efficacy of chain-extended amino acid analogues and phosphate blocking groups. In this paper we report the preparation and evaluation of five new phosphoramidates of d4T, related to the phenyl methoxyglycinyl phosphate, but with methylene spacers ranging between two and six carbons in length between the amino nitrogen and the ester unit. 
Materials and Methods
Diethyl ether (Et 2 O) and dichloromethane (DCM) were distilled from calcium hydride and stored over activated 4Å molecular sieves. Triethylamine (NEt 3 ) was distilled from calcium hydride and used immediately. Tetrahydrofuran (THF) was distilled at atmospheric pressure from sodium in benzophenone. d4T was supplied by Cardiff Chemicals (Cardiff, UK) and dried over P 2 O 5 under vacuum at 50°C for 4 h prior to use. Thin layer chromatography (TLC) was performed using commercially available Merck silica gel 60 F 254 plates and the separated components were visualized using UV (254 nm), or by treatment with a 5% ethanolic solution of dodeca-molybdo-phosphoric acid followed by heating. Column chromatography was performed using Woelm Silica (32-63 mm) as the stationary phase.
All spectral data were obtained in CDCl 3 . 1 H and 13 C NMR were recorded on a Bruker Avance DPX spectrometer with operating frequencies of 300 MHz and 75 MHz, respectively, and referenced to TMS.
31 P NMR spectra were recorded on a Bruker Avance DPX spectrometer operating at 121 MHz and are reported in units of δ relative to 85% phosphoric acid as the external standard; positive shifts are downfield. Low resolution mass spectra were run on a VG Platform II Fisons instrument (Fisons, Altringham, UK) (atmospheric pressure ionization, electrospray mass spectrometry) in either negative or positive ion mode. High resolution mass spectra were obtained courtesy of the University of Birmingham Department of Chemistry (Birmingham, UK). HPLC chromatograms were recorded using an ACS quaternary system, with an ODS5 column and an eluent of water/acetonitrile, with 82% water between 0-10 min, and then a linear gradient to 20% water at 30 min, with a flow rate of 1 ml/min and detection by UV at 254 nm. The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), dd (doublet of doublet). Asterisk refers to diastereoisomeric splitting of peaks.
Phenyl (methoxy N-β-alaninyl) phosphorochloridate
A solution of triethylamine (2.90 g, 4 ml, 28.67 mmol) in DCM (40 ml) was added to a cold (-90°C) stirring solution of β-alanine methyl ester hydrochloride (2.0 g, 14.34 mmol) and phenyl phosphorodichloridate (3.02 g, 2.14 ml, 14.34 mmol) in DCM (100 ml). The reaction mixture was stirred at this temperature for 1 h and then at room temperature for 16 h. The solvent was removed under reduced pressure and diethyl ether (100 ml) was added to give a white precipitate. Filtration and evaporation of the filtrate under reduced pressure and nitrogen gave a light yellow oil (2.88 g, 73%). δ P 11.42.
Phenyl (methoxy N-4-aminobutyryl) phosphorochloridate
This was prepared by a method analogous to that for the β-alaninyl compound above. Thus, from 2 g of 4-aminobutyryl methyl ester hydrochloride, was isolated 3.32 g of product (87%). δ P 12.25.
Phenyl (methoxy N-5-aminovaleryl) phosphochloridate
This was prepared by a method analogous to that for the β-alaninyl compound above. Thus, from 2 g of 5-aminovaleryl methyl ester hydrochloride, was isolated 2.10 g (58%). δ P 12.25.
Phenyl (methoxy-N-6-aminocaproyl) phosphorochloridate
This was prepared by a method analogous to that for the β-alaninyl compound above, except that stirring was for 2 h at room temperature. Thus, from 2 g of 6-aminocaproyl methyl ester hydrochloride, was isolated 3.2 g of product (91%). δ P 12.32.
Phenyl (methoxy-N-7-aminoheptanoyl) phosphorochloridate
This was prepared by a method analogous to that for the β-alaninyl compound above. Thus, from 0.7 g of 7-heptanoyl methyl ester hydrochloride, was isolated 1.17 g of product (98%). δ P 12.10.
2′,3′-Didehydro-2′,3′-dideoxythymidine-5′-(phenyl methoxy N-β-alaninyl) phosphate (2a) Phenyl (methoxy N-β-alaninyl) phosphorochloridate (1.24 g, 4.46 mmol) in THF (10 ml) was added to a stirring solution of d4T (0.5 g, 2.23 mmol) and N-methylimidazole (0.92 g, 0.89 ml, 11.16 mmol) in THF (15 ml). The reaction mixture was stirred at room temperature for 15 h. Further phosphorochloridate (0.62 g, 2.23 mmol) in THF (5 ml) was added and stirring was continued for 2 h. The solvent was evaporated under reduced pressure to give a gummy solid which was dissolved in chloroform (50 ml), washed with 1 M HCl (2×50 ml) followed by saturated sodium hydrogen carbonate solution (2×50 ml) and brine (2×50 ml), and dried (MgSO 4 ). Filtration and evaporation of the filtrate under reduced pressure gave an oil. This was dissolved in chloroform (around 3 ml), placed on top of a column containing silica and eluted with ethyl acetate (200 ml) followed by a mixture of ethyl acetate : ethanol (96 : 4). Pooling and evaporation of appropriate fractions gave a white foamy solid (0.66 g, 64%). δ P 6. 44, 6.70 
This was prepared by a method analogous to that for compound (2a) above. Thus, from 0.5 g of d4T, was isolated 0.69 g of product (65%). δ P 6.66, 6.11 (2 : 1); δ H 9.91 (1H, bs, NH), 7.37-7.11* (6H, m, Ph, H-6), 6. 2′,3′-Didehydro-2′,3′-dideoxythymidine-5′-(phenyl methoxy N-5-aminovaleryl) phosphate (2c)
This was prepared by a method analogous to that for compound (2a) above, except the chromatographic purification utilized was EtOH : hexane (20 : 80) Thus, from 0.3 g of d4T, was isolated 0.33 g of product (50%). 2′,3′-Didehydro-2′,3′-dideoxythymidine-5′-(phenyl methoxy N-6-aminocaproyl) phosphate (2d)
This was prepared by a method analogous to that for compound (2a) above, except no further phosphorochloridate was added. Thus, from 0.5 g of d4T, was isolated 0.91 g of product (80% 2′,3′-Didehydro-2′,3′-dideoxythymidine-5′-(phenyl methoxy N-7-aminoheptanoyl) phosphate (2e)
This was prepared by a method analogous to that for compound (2a) above, except the reaction was stirred for 3 h and the chromatographic elution utilized was ethanol in chloroform (4 : 96). Thus, from 0.2 g of d4T, was isolated 29.8 mg of product (6%). δ P 6. 65, 5.97 (3 : 4) 
Antiviral assays
HIV-1 strain IIIB was obtained from RC Gallo (at the time at the National Cancer Institute, National Institutes of Health, Bethesda, Md., USA). HIV-2 strain ROD was provided by L Montagnier (Pasteur Institute, Paris, France). CEM/0 cells were obtained from the ATCC, and CEM/TK -cells were a kind gift from S Eriksson and A Karlsson (Karolinska Institute, Stockholm, Sweden). CEM cells were infected with HIV-1 as previously described . Briefly, 4×10
5 CEM cells/ml were infected with HIV-1 or HIV-2 at 100 CCID 50 (50% cell culture infective dose) per ml of cell suspension. Then, 100 µl of the infected cell suspension were transferred to microtitre plate wells and mixed with 100 µl of the appropriate dilutions of the test compounds. After 4 days, giant cell formation was recorded microscopically in the HIV-infected cell cultures. The 50% effective concentration (EC 50 ) and 50% cytotoxic concentration (CC 50 ) were defined as the compound concentrations required to reduce by 50% the number of giant cells in the virus-infected cell cultures, and the number of viable cells in the mock-infected cell cultures, respectively.
To determine the activity of the compounds against Moloney murine sarcoma virus (MSV), murine C3H/3T3 embryo fibroblast cells were seeded at 5×10 5 cells/ml into 48-well microplates. After 24 h, the cell cultures were infected with 80 f.f.u. of MSV for 60 min at 37°C. Then, the medium was replaced by 1 ml of fresh culture medium containing various concentrations of the test compounds. After 6 days, transformation of the cell cultures was examined microscopically. The EC 50 was defined as the compound concentration required to inhibit MSV-induced cell transformation by 50%.
Treatment of (3a-b) and (2a-c) with pig liver esterase
Test compounds (approximately 9 µmol) were dissolved in a mixture of acetone (0.1 ml) and 0.05 M TRIZMA buffer pH 7.6 (1 ml; made up in D 2 O) and exposed to 40 mg of pig liver esterase (Sigma; activity 15 units/mg). The mixture was maintained at 37°C for evaluation directly by 31 P NMR at intervals (1-24 h). After 24 h, water (10 ml) was added and the solution extracted with dichloromethane (2×10 ml). The combined organic phase was extracted with water (10 ml) and the combined aqueous layers evaporated to dryness under reduced pressure. The organic fractions were evaporated under reduced pressure. Both sets of crude products were examined by TLC, 31 P NMR and mass spectrometry. TLC revealed the organic fractions to contain exclusively unreacted phosphate triesters (2a-c) and aqueous fractions to contain hydrolysis products (5a-c). Data are presented for the starting materials ('organic' phase) and sole products 
Results
By methods entirely analogous to those we have extensively published for normal α-amino acid compounds, we prepared the phenyl phosphorochloridate derivative from PhOPOCl 2 and β-alanine methyl ester hydrochloride in the presence of triethylamine (McGuigan et al., 1993 . This phosphorochloridate was allowed to react with d4T (1) in THF containing N-methylimidazole, under standard conditions , to give the target blocked phosphoramidate (2a) in moderate yield after chromatographic purification (Fig. 1) . This material displayed two closely spaced signals by 31 P NMR, corresponding to the diastereoisomers which arise from mixed stereochemistry at the chiral phosphate centre. These isomers were not resolved, and were later evaluated as a mixture, as for subsequent analogues described below.
The presence of (dia)stereoisomers in the sample was also evident from 13 C NMR and HPLC data. Interestingly, the isomeric ratios determined by 31 P NMR and HPLC differed somewhat, although this may correspond to some overlap of signals, particularly in the HPLC. High resolution mass spectrometry (MH + ) and 1 H NMR further confirmed the structure and purity of the sample.
Similarly prepared (Fig. 1) were the analogous γ-aminobutyryl (GABA) (2b), valeryl (2c), caproyl (2d) and heptanoyl (2e) derivatives. Yields across the series were generally in the range 50-80%, though the long chain compound (2e) was only isolated in low yield, the reasons for which are unclear aside from increased steric hindrance to phosphorylation. Each of the analogues 2b-2e was characterized by analytical and spectroscopic (NMR and mass spectrometry) methods, and each displayed evidence of a diastereomeric mixture as noted above for 2a. In one case (2d), only one HPLC peak was noted; however, the splitting of 31 P and 13 C NMR signals confirmed that this was simply owing to coincidence of the HPLC peaks in this instance. Full 13 C NMR data for the series 2a-2e are available as supplementary data from the Editor-in-Chief.
Discussion
The target compounds 2a-e were tested for their inhibition of HIV-1 and HIV-2 replication in vitro using procedures which we have described previously (McGuigan et al., 1993; Balzarini et al., 1996a) . d4T (1) and the previously reported alanine and glycine phosphoramidate derivatives (3a-b) were also included as biological controls. As shown in Table 1 , the chain-extended phosphoramidates 2a-2e were devoid of antiviral action at the highest concentrations tested. This is in notable contrast to the α-amino acid analogues (3a-b). As we have previously shown McGuigan et al., 1996a McGuigan et al., , 1997 , alanine is among the most effective phosphoramidate group, the alanine derivatives being approximately 10 times more potent than the corresponding glycine compounds (3a versus 3b). The chain-extended series (2a-2e) can be regarded as analogues of glycine with methylene spacers inserted.
Thus, it is clear that insertion of even one extra methylene unit in 2a leads to a very significant reduction in antiviral potency. The insertion of further methylene units (2b-2e) does not lead to any further detectable change in activity. In this regard, the chain-extended amino acid derivatives we report herein are no more effective than simple alkylamino compounds (McGuigan et al., 1996c) and it is clear that an α-amino acid (or a close analogue thereof ) appears to be required for antiviral potency. Apparently, the presence of the α-ester unit in 3a-3b significantly increases the efficiency of intracellular nucleoside phosphate release, by comparison to a simple alkylamine analogue, but the presence of an ester unit in the β-position of 2a, the γ-position of 2b and so on through the series, is unable to be similarly effective. Whether the necessity for the α-ester unit is based on steric or electronic grounds (or both) is unclear, but is the subject of much current activity in our laboratories.
As further noted in Table 1 , the series 2a-2e are devoid of detectable antiretroviral activity in thymidine kinase (TK)-deficient (TK -) cells. In contrast, the α-amino acidderived compounds (3a-b) retained good activity in this cell line, indicating that they act as true nucleotide delivery motifs, and bypass the dependence of the parent nucleoside (1) upon TK (Table 1) . Finally, the chain-extended analogues (2a-2e) were also inactive against MSV whereas d4T (1) and the alanine phosphoramidate 3b was active.
Our earlier in vitro studies with 3b revealed the generation of alaninyl phosphate (4b) as a major intracellular metabolite, and as a likely source of d4T monophosphate, and hence the bio-active triphosphate. We wondered if the notable inactivity in the chain-extended series (2a-2e) might correspond to the fact that the intracellular activation to the analogues of 4b was somehow impeded for this series.
Given that non-specific human carboxyl esterases show a remarkable similarity to those of other mammals ( Junge et al., 1974) , we wondered if pig liver esterase might be used as a model for the in vitro hydrolysis of compounds such as 3b, and whether such a simple assay might throw light on the dramatic inactivity of the new series (2a-2e). Thus, we studied the stability of 3a-3b and 2a-2c towards hydrolysis by pig liver esterase (EC 3.1.1.1), using in situ 31 P NMR. Under the conditions of the assay, both 3a and 3b showed rapid hydrolysis to generate the amino acyl phosphoramidates (4a-4b). We propose that this takes place via the initial hydrolysis of the methyl carboxyl ester, followed by rapid loss of the phenyl (phosphate) moiety. Whether this loss is in one step, or via the intermediacy of an unstable cyclic phosphoramidate system is not yet clear. However, in sharp contrast, compounds 2a-2c failed to liberate any detectable analogues of 4a-4b. There was rapid hydrolysis of the starting esters, but this did not proceed with loss of phenol, as indicated by the retention of the chirality at the phosphate centre, giving the usual multiplicity of 31 P NMR peaks. Moreover, the ratios of these peaks were retained entirely from those of the initial compounds 2a-2c. Furthermore, mass spectrometry of the crude products failed to reveal any traces of the suggested amino acyl intermediates, analogous to 4a-4b, instead displaying clear peaks in each case corresponding to starting material (2a-2c) and demethylated products (5a-5c). Thus, it appears that the chain extension of the series impedes the second stage in the activation process, namely the loss of the phenyl group from the de-esterified phosphoramidate prodrugs. It follows that the suggested key intermediates (4a-4b) cannot be formed, and that triphosphate generation is thus greatly reduced. This then entirely rationalizes the lack of antiviral action for the chain-extended series 2a-2e.
Thus, we feel that the esterase assay is important and informative for several reasons. It offers a rationalization for the dramatic loss of antiviral action for the chainextended series. It offers a simple, cell-free protocol for the possible prediction of in vitro metabolism and potential antiviral action. Finally, it adds further support to our suggestion that the amino acyl phosphoramidates (4a-4b) are a necessary pre-requisite for phosphoramidate compounds to act as nucleotide prodrugs.
In conclusion, the inclusion of a methylene spacer between the nitrogen and ester groups of anti-HIV phosphoramidate derivatives such as 3a-3b led to a complete loss of antiviral activity. This finding appears to highlight the necessity of an α-amino acid for the phosphoramidates to be antivirally effective. Lastly, a simple esterase assay is able to rationalize the data, offers the potential for predictive value, and supports the suggestion that the amino acyl phosphoramidate intermediates are important for the success of this pro-nucleotide approach.
